BACKGROUND: Despite the strong association between secondary dengue virus (DENV) infections and dengue hemorrhagic fever (DHF), the majority of secondary infections are subclinical or mild. The determinants of clinical severity remain unclear, though studies indicate a titer-dependent and time-dependent role of cross-protective anti-DENV antibodies. METHODS: Data from 2 sequential prospective cohort studies were analyzed for subclinical and symptomatic DENV infections in schoolchildren in Kamphaeng Phet, Thailand (1998-2002 and 2004-2007). Children experiencing ≥ 1 DENV infection were selected as the population for analysis (contributing 2169 person-years of follow-up). RESULTS: In total, 1696 children had ≥ 1 DENV infection detected during their enrollment; 268 experienced 2 or more infections. A shorter time interval between infections was associated with subclinical infection in children seronegative for DENV at enrollment, for whom a second-detected DENV infection is more likely to reflect a true second infection (average of 2.6 years between infections for DHF, 1.9 for DF, and 1.6 for subclinical infections). CONCLUSIONS: These findings support a pathogenesis model where cross-reactive antibodies wane from higher-titer, protective levels to lower-titer, detrimental levels. This is one of the first studies of human subjects to suggest a window of cross-protection following DENV infection since Sabin's challenge studies in the 1940s.
BACKGROUND: Despite the strong association between secondary dengue virus (DENV) infections and dengue hemorrhagic fever (DHF), the majority of secondary infections are subclinical or mild. The determinants of clinical severity remain unclear, though studies indicate a titer-dependent and time-dependent role of cross-protective anti-DENV antibodies. METHODS: Data from 2 sequential prospective cohort studies were analyzed for subclinical and symptomatic DENV infections in schoolchildren in Kamphaeng Phet, Thailand (1998-2002 and 2004-2007). Children experiencing ≥ 1 DENVinfection were selected as the population for analysis (contributing 2169 person-years of follow-up). RESULTS: In total, 1696 children had ≥ 1 DENVinfection detected during their enrollment; 268 experienced 2 or more infections. A shorter time interval between infections was associated with subclinical infection in children seronegative for DENV at enrollment, for whom a second-detected DENVinfection is more likely to reflect a true second infection (average of 2.6 years between infections for DHF, 1.9 for DF, and 1.6 for subclinical infections). CONCLUSIONS: These findings support a pathogenesis model where cross-reactive antibodies wane from higher-titer, protective levels to lower-titer, detrimental levels. This is one of the first studies of human subjects to suggest a window of cross-protection following DENVinfection since Sabin's challenge studies in the 1940s.
Entities:
Keywords:
antibodies; dengue; epidemiology; immunity; pathogenesis; prospective cohort study
Authors: Anna P Durbin; Alexander Schmidt; Dan Elwood; Kimberli A Wanionek; Janece Lovchik; Bhavin Thumar; Brian R Murphy; Stephen S Whitehead Journal: J Infect Dis Date: 2010-12-14 Impact factor: 5.226
Authors: M G Guzmán; G Kouri; L Valdes; J Bravo; M Alvarez; S Vazques; I Delgado; S B Halstead Journal: Am J Epidemiol Date: 2000-11-01 Impact factor: 4.897
Authors: Nguyen Thi Kim Tien; Christine Luxemburger; Nguyen Trong Toan; Laurence Pollissard-Gadroy; Vu Thi Que Huong; Pham Van Be; Nguyen Ngoc Rang; Tram-Anh Wartel; Jean Lang Journal: Trans R Soc Trop Med Hyg Date: 2010-07-13 Impact factor: 2.184
Authors: Zhihua Kou; Matthew Quinn; Huiyuan Chen; W W Shanaka I Rodrigo; Robert C Rose; Jacob J Schlesinger; Xia Jin Journal: J Med Virol Date: 2008-01 Impact factor: 2.327
Authors: Timothy P Endy; Kathryn B Anderson; Ananda Nisalak; In-Kyu Yoon; Sharone Green; Alan L Rothman; Stephen J Thomas; Richard G Jarman; Daniel H Libraty; Robert V Gibbons Journal: PLoS Negl Trop Dis Date: 2011-03-01
Authors: Maria G Guzman; Mayling Alvarez; Rosmari Rodriguez-Roche; Lidice Bernardo; Tibaire Montes; Susana Vazquez; Luis Morier; Angel Alvarez; Ernest A Gould; Gustavo Kouri; Scott B Halstead Journal: Emerg Infect Dis Date: 2007-02 Impact factor: 6.883
Authors: Mammen P Mammen; Chusak Pimgate; Constantianus J M Koenraadt; Alan L Rothman; Jared Aldstadt; Ananda Nisalak; Richard G Jarman; James W Jones; Anon Srikiatkhachorn; Charity Ann Ypil-Butac; Arthur Getis; Suwich Thammapalo; Amy C Morrison; Daniel H Libraty; Sharone Green; Thomas W Scott Journal: PLoS Med Date: 2008-11-04 Impact factor: 11.069
Authors: Leah C Katzelnick; Magelda Montoya; Lionel Gresh; Angel Balmaseda; Eva Harris Journal: Proc Natl Acad Sci U S A Date: 2016-01-04 Impact factor: 11.205
Authors: Freddy Perez; Anthony Llau; Gamaliel Gutierrez; Haroldo Bezerra; Giovanini Coelho; Steven Ault; Sulamita Brandao Barbiratto; Marcelo Carballo de Resende; Lizbeth Cerezo; Giovanni Luz Kleber; Oscar Pacheco; Octavio Lenin Perez; Victor Picos; Diana P Rojas; Joao Bosco Siqueira; Marco Fidel Suarez; Eva Harris; Luis Gerardo Castellanos; Carlos Espinal; Jose Luis San Martin Journal: Trop Med Int Health Date: 2019-01-28 Impact factor: 2.622
Authors: Raphaël M Zellweger; William W Tang; William E Eddy; Kevin King; Marisa C Sanchez; Sujan Shresta Journal: J Virol Date: 2015-04-08 Impact factor: 5.103
Authors: Leah C Katzelnick; Judith M Fonville; Gregory D Gromowski; Jose Bustos Arriaga; Angela Green; Sarah L James; Louis Lau; Magelda Montoya; Chunling Wang; Laura A VanBlargan; Colin A Russell; Hlaing Myat Thu; Theodore C Pierson; Philippe Buchy; John G Aaskov; Jorge L Muñoz-Jordán; Nikos Vasilakis; Robert V Gibbons; Robert B Tesh; Albert D M E Osterhaus; Ron A M Fouchier; Anna Durbin; Cameron P Simmons; Edward C Holmes; Eva Harris; Stephen S Whitehead; Derek J Smith Journal: Science Date: 2015-09-18 Impact factor: 47.728